Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.

ABSTRACT:

Scope

Down syndrome (DS), caused by trisomy of human chromosome 21 (Hsa21), is characterized by a spectrum of phenotypes including skeletal abnormalities. The Ts65Dn DS mouse model exhibits similar skeletal phenotypes as humans with DS. DYRK1A, a kinase encoded on Hsa21, has been linked to deficiencies in bone homeostasis in DS mice and individuals with DS. Treatment with Epigallocatechin-3-gallate (EGCG), a known inhibitor of Dyrk1a, improves some skeletal abnormalities associated with DS in mice. EGCG supplements are widely available but the effectiveness of different EGCG-containing supplements has not been well studied.

Methods and results

Six commercially available supplements containing EGCG were analyzed, and two of these supplements were compared with pure EGCG for t

SUBMITTER: Abeysekera I 

PROVIDER: S-EPMC4828301 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature